Table 4 Subgroup analysis of fish oil supplementation and placebo by intervention duration
Outcome | No. of studies | Overall effect | Heterogeneity(%) | |
|---|---|---|---|---|
Effect size(95%CI) | p | I2 | ||
FPG | 13 | 0.13(− 0.03,0.28) | 0.11 | 22.5 |
 ≤1 month | 3 | 0.35(−0.18,0.88) | 0.19 | 21.9 |
 1-3 months | 6 | 0.17(−0.04,0.38) | 0.11 | 23.0 |
 > 3 months | 4 | 0.00(−0.26,0.27) | 0.99 | 27.6 |
FINS | 8 | −0.00(− 0.22,0.21) | 0.98 | 38.3 |
 ≤1 month | 2 | −0.53(−1.08,0.01) | 0.06 | 0 |
 1-3 months | 2 | −0.04(− 0.30,0.23) | 0.79 | 0 |
 > 3 months | 4 | 0.14(−0.19,0.47) | 0.41 | 51.7 |
HbAc1 | 10 | 0.01(−0.14,0.17) | 0.88 | 0 |
 ≤1 month | 1 | 0.89(− 0.03,1.82) | 0.06 | – |
 1-3 months | 5 | − 0.00(− 0.22,0.22) | 1.00 | 0 |
 > 3 months | 4 | −0.03(− 0.26,0.20) | 0.81 | 0 |
HOMA-IR | 8 | −0.02(− 0.18,0.14) | 0.82 | 0 |
 ≤1 month | 2 | −0.28(− 0.82,0.26) | 0.31 | 0 |
 1-3 months | 2 | − 0.06(− 0.37,0.25) | 0.71 | 22 |
 > 3 months | 4 | 0.06(− 0.16,0.28) | 0.59 | 0 |
TG | 15 | −0.40(− 0.53,-0.28) | 0 | 0 |
 ≤1 month | 2 | −0.53(−1.07,0.02) | 0.06 | 0 |
 1-3 months | 8 | −0.40(− 0.56,-0.23) | 0.00 | 0 |
 > 3 months | 5 | −0.43(− 0.68,-0.17) | 0.00 | 36.8 |
TC | 15 | −0.07(− 0.19,0.05) | 0.28 | 0 |
 ≤1 month | 2 | 0.05(− 0.50,0.60) | 0.86 | 4.7 |
 1-3 months | 8 | −0.05(− 0.23,0.14) | 0.61 | 16.7 |
 > 3 months | 5 | −0.12(− 0.32,0.07) | 0.20 | 0 |
HDL cholesterol | 15 | 0.21 (0.05,0.37) | 0.01 | 37.1 |
 ≤1 month | 2 | 0.29(−0.25,0.83) | 0.29 | 0 |
 1-3 months | 8 | 0.14(−0.07,0.35) | 0.20 | 33.3 |
 > 3 months | 5 | 0.29(−0.04,0.61) | 0.09 | 60.6 |
LDL cholesterol | 15 | 0.02(−0.10,0.14) | 0.72 | 0 |
 ≤1 month | 2 | 0.23(−0.40,0.86) | 0.47 | 26.2 |
 1-3 months | 8 | 0.09(−0.08,0.25) | 0.29 | 0 |
 > 3 months | 5 | −0.10(− 0.29,0.10) | 0.33 | 0 |